Financial reports
ARS
2023 FY
Annual report to shareholders
18 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
Current reports
8-K
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Results of Operations and Financial Condition
30 Jan 24
8-K
Kura Oncology Announces Oversubscribed
26 Jan 24
8-K
Other Events
22 Dec 23
8-K
Kura Oncology Reports Third Quarter 2023
2 Nov 23
8-K
Entry into a Material Definitive Agreement
1 Sep 23
8-K
Kura Oncology Reports Second Quarter 2023
3 Aug 23
8-K
Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
14 Jun 23
8-K
Other Events
12 Jun 23
8-K
Departure of Directors or Certain Officers
2 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
27 Feb 24
424B3
Prospectus supplement
15 Feb 24
S-3
Shelf registration
9 Feb 24
D
Exempt offering of security
5 Feb 24
S-3ASR
Automatic shelf registration
2 Nov 23
424B5
Prospectus supplement for primary offering
14 Jun 23
424B5
Prospectus supplement for primary offering
13 Jun 23
S-8
Registration of securities for employees
2 Jun 23
S-8
Registration of securities for employees
23 Feb 23
424B5
Prospectus supplement for primary offering
3 Nov 22
Proxies
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
4 May 23
DEFA14A
Additional proxy soliciting materials
6 Apr 23
DEF 14A
Definitive proxy
6 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
4 Jun 21
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
Other
UPLOAD
Letter from SEC
29 Feb 24
EFFECT
Notice of effectiveness
15 Feb 24
CORRESP
Correspondence with SEC
14 Feb 24
CORRESP
Correspondence with SEC
13 Feb 24
CT ORDER
Confidential treatment order
21 Feb 23
EFFECT
Notice of effectiveness
19 Aug 20
CORRESP
Correspondence with SEC
14 Aug 20
UPLOAD
Letter from SEC
14 Aug 20
CT ORDER
Confidential treatment order
17 Mar 20
CT ORDER
Confidential treatment order
17 Mar 20
Ownership
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Flynn James E
12 Feb 24
4
THOMAS JAMES DOYLE
31 Jan 24
4
KATHLEEN FORD
31 Jan 24
4
Teresa Brophy Bair
31 Jan 24
4
STEPHEN DALE
31 Jan 24
144
Notice of proposed sale of securities
30 Jan 24